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All calcium antagonists have the ability to decrease the
symptoms and signs in some patients with ischemicheart
disease and help lower the blood pressure in hypertensive
persons, but in clinical doses nifedipine does not exhibit
antiarrhythmic properties, although these are an im-
portant part of the action of verapamil, diltiazem and
some substances with a similar chemical structure. In
certain disorders beta-adrenergic blockingdrugs are useful
adjuncts, and under some circumstances, particularly
variant angina and supraventricular arrhythmias, spe-
It is just a century since the London physiologist and phy-
sician, Sydney Ringer (1), showed that calcium was essen-
tial for the proper function of the myocardium, and it took
nearly 90 years to translate the lessons from his studies into
specific therapeutic action. From their work on a series of
compounds of different chemical structures, Albrecht Fleck-
enstein and his co-workers in Freiburg (2,3) characterized
a property they called calcium antagonism. There are four
possible means by which calcium may move inward across
the myocardial cell membrane (4): passive transport, cal-
cium-sodium exchange, calcium-potassium exchange and
passage through the voltage-activated slow inward channel.
Only the latter mechanism is inhibited by the so-called cal-
cium antagonists, and we follow Nayler's definition (4) of
these substances as having the "ability to inhibit the inward
transport of Ca2 + through voltage-activated slow channels,
an inhibitory effect that is counteracted or overcome by
raising the extracellular Ca2+ ."
Such action has many synonyms (4,5), of which, in the
United States, "calcium channel blocker" now seems most
popular. Whatever the general name, there are two crucial
aspects: 1) possession of action as defined (l ,4), and 2)
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cific calcium antagonists are the drugs of choice. More
data are needed to define the role of calcium antagonists
during cardiopulmonary bypass, in the protection of the
ischemic myocardium, in the management of hyper-
trophic cardiomyopathy and in specificcases of primary
pulmonary hypertension. When used with an appropri-
ate sense of perspective and careful observation, calcium
antagonists provide useful additional means of helping
selected patients suffering from particular cardiovas-
cular diseases.
avoidance of confusion with other agents that may inciden-
tally and in other ways affect calcium transport, for example,
lidoflazine, which at the membrane level is essentially an
inhibitor of the fast inward, sodium-dependent channel (6).
Mechanism of Action of Calcium Antagonists
Calcium antagonists have a variety of actions on excitation-
contraction coupling, tending to produce vasodilatation, re-
duction of force in myocardial contraction and, in certain
cases, depression of impulse formation and conduction. These
are basically dependent on the fact that calcium influx leads
to activation of myofibrillar adenosine triphosphatase which
converts phosphate-bound energy into mechanical work,
with a consequent increase in oxygen requirements. Calcium
antagonists, on the other hand, limit calcium entry into
cardiac and smooth muscle cells, thereby reducing the split-
ting of adenosine triphosphate and myocardial oxygen de-
mand; the force of myocardial (and vascular smooth muscle)
contraction is concomitantly attenuated. It must be remem-
bered, of course, that some of these actions are compensated
for in the intact human heart by such means as reflex sym-
pathetic activity, and in practice cardiac output is not sig-
nificantly changed (7,8). These mechanisms have already
been extensively reviewed (4,5,9) and we will later con-
centrate on the clinical role of the agents.
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Available Agents
At present, three calcium antagonists (nifedipine , verapamil
and diltiazem) are available in the United States. The se
drug s and others have. however, been in use elsewhere for
a long time , verapamil for more than 15 years. Since Fleck-
enstein' s pioneering laboratory studies (10) several group s
of compounds have been developed . not necessarily sharing
a common molecular configuration: these include the pa-
paverine deri vatives verapamil. methoxyverapamil (D600)
and tiapamil ; the 1.4 dihydropyridine nifedipine and several
congeners; diltiazem: the diphenylamines prenylamine and
fendiline; and perhexiline (2.11-16) . Fleckenstein (17) re-
cently stressed the dominant position of the three main cal-
cium antagonists. verapamil, nifedipine and diltiazem in
contrast to the less specific weaker members such as pren-
ylamine . Because these three "major" calcium antagonists
have been evaluated extensively in clinical practice. we will
review aspects of their use for several indications relevant
to the cardiovascular system .
Angina Pectoris
In the vast majority of patients who suffer from angina
pectoris , the underlying disease is coronary arteriosclerosis.
which so ob structs the artery that myocardial blood flow
cannot be increased enough to cope with increa sed oxygen
requirements such as those that occur during exercise . The
benefit s of nitrates and beta-receptor blocking drugs in an-
gina tend to be effected by reducing myocardial work. Al-
though calcium antagonists share this property. they also
may increase perfusion by producing coronary vasodilata-
tion. as demonstrated in animal studies (18-20). When there
is coronary artery disease, even though coronary arteriolar
resistance may be decreased at rest. evidence for an increase
in coronary blood flow does exi st although the data are
conflicting (21.22).
A most elegant demonstration of the difference in action
between calcium antagonists . nitrates and beta-receptor
blocking drugs was given by Engel and Lichtlen (23) . who
studied 36 patients with isolated stenosis of the anterior
descending or circumflex branch of the left coronary artery.
All agents were given sublingually and the patients were
assessed at rest and during pacing-induced ischemia. Re-
gion al myocardial blood flow was measured using xenon-
133 washout at rest and during ischemia. and atrial pacing
was performed at identical heart rates before and after drug
administration . Nifedipine was shown to decrease peripheral
resistance and also to increase myocardial blood flow by
reducing coronary resistance , while nitrates reduced preload
and afterload and beta-receptor blocking drugs reduced
myocardial oxygen consumption by direct cardiac action.
These observations were in patients with obstructive coro-
nary disease; in addition. calcium antagonists have been
shown to reverse or prevent coronary artery spasm on the
basis of direct observations using coronary arteriography or
inference from hemodynamic or non invasive monitoring of
patients with variant angina (24.25).
Clinical Experience in Angina
Variant and unstable angina. Angina at rest associated
with ST segment changes. more usuall y elevation than
depression . is believed often to be caused by temporary
enhancement of coronary artery tone leading to varying
degrees of obstruction (26). It is likewise clear that in un-
stable angina this factor may be operative with or without
coronary arteriosclerosis (27). Remission of ischemic events
is usually complete when calcium antagonists are admin-
istered to most patients shown to have spasm (24.25.28 -
30) and the symptoms may recur promptly if the medication
is withdrawn (24,25). Impre ssive responses to nifedipine
(29) , although demonstrated without control subjects , were
seen in 8 patients with variant ang ina whose coronary ar-
terie s were normal or only mildly abnormal. as well as in
a later study of 127 patients with coronary spasm (31). in
whom nifedipine decreased the frequency of anginal epi-
sodes from an average of 16 a week to 2; control proved
complete in 63% of these subjects . Substantial improvement
was documented elegantly in 27 patients in whom nifedi-
pine . diltiazem and verapamil were able to block ergono-
vine- induced episodes of variant angina (32). and also in 4
similar subjects in another stud y (33) on careful titration
of different doses of ergono vine . In six patients belie ved to
suffer from coronary artery spasm on exertion. the chest
pain and ST segment elevation were prevented by oral ver-
apamil (34).
Clinical experience with variant angina also has been
[avorable and two controlled studies have shown good re-
sponse. In 12 patients with unstable angina and frequent
epi sodes of ST segment displacement at rest. verapamil in
a dose of 480 mg/day. given during two separate treatment
periods. reduced the number of epi sode s from 123 and 130
during treatment with placebo to 31 and 23 during drug
treatment . respectively: this was a double-blind stud y con-
ducted in a coronary care unit (35). An even more con-
vincing demonstration of the value of a calcium antagonist
was seen in a prospective . double-blind. randomized pla-
cebo-controlled trial in 138 patient s with unstable angina;
medical treatment failed in 43 of 70 patients given placebo
but in only 30 of 68 given nifedipine (36).
Thu s, while earl y result s were favorable but sometimes
open to question becau se of study design . the beneficial
effects of calcium antagonists have been effectively dem-
onstrated in variant and unstable angina (32.33.36) and it
is quite clear that they have a valu able role in the manage-
ment of these disorders.
Chronic stable angina. Although variant or unstable
angina provides an immediate challenge requiring treatment.
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most patients suffering from angina do so on a chronic basis
in association with coronary artery disease, and the possi-
bility of treatment with calcium antagonists in addition to
beta-receptor blocking drugs and other measures requires
careful assessment, in some cases as a possible alternative
to coronary artery bypass grafting. While a few years ago
there were no properly controlled clinical trials of calcium
antagohists in chronic stable angina, several have been re-
ported in recent years, and these agents now can be seen
to have an important role.
While early studies using verapamil at low doses gave
equivocal results (37), during double-blind clinical trials
doses of 360 mg/day reduced the frequency of anginal at-
tacks and the consumption of nitroglycerin by approximately
50% and significantly improved exercise ability (38,39).
These benefits were maintained without notable adverse
effects at follow-up after I year of treatment (40). Other
studies (41) have found similar results in comparison with
placebo.
Nifedipine has also been proved effective. In a single-
blind controlled trial in 10 patients with chronic stable an-
gina (42), nifedipine in a dose of 60 mg/day reduced the
average frequency of attacks from II to 6 episodes a patient
a week, and the consumption of nitroglycerin from 9 to 4
tablets a week; there was also a moderate increase in the
duration of exercise that could be undertaken. In our own
double-blind studies (43) on 16 patients, nifedipine in a
dose of 60 mg/day reduced the frequency of attacks of
angina and the number of nitroglycerin tablets consumed,
respectively, from 22 to 12 episodes and from 18 to II
tablets a week. We also demonstrated a reduction in the
area of exercise-induced myocardial ischemia by 35%, as
assessed by 16-point precordial electrocardiographic map-
ping; the number of episodes of ST depression seen on
ambulatory electrocardiographic monitoring decreased by
51%. Of the episodes of ST depression, 60% had been
asymptomatic, and these responded to nifedipine in exactly
the same way as did episodes associated with chest pain.
Somewhat larger numbers of patients were analyzed, al-
though in less detail, in a multicenter trial of nifedipine (44)
and favorable responses were of the same order.
There is every reason to believe that diltiazem is also
effective in chronic stable angina, as judged by symptoms,
improvement in exercise ability and amelioration of elec-
trocardiographic changes of ischemia, using a different form
of assessment: a maximal exercise test 3 hours after a single
oral dose of 120 mg of diltiazern, given in double-blind
fashion and compared with placebo (45). Using a protocol
very similar to ours (43), others (46) have shown comparable
efficacy of verapamil, 360 mg/day, and nifedipine, 60 mg/
day, as judged by similar subjective and objective indexes.
This is consistent with the observation that 10 mg of nife-
dipine and 160 mg of verapamil given orally increase ex-
ercise duration similarly when compared with placebo (47).
Combined treatment with calcium antagonists and beta-
receptor blocking agents. The possibility of combining cal-
cium antagonists and beta-adrenergic blocking drugs raises
interesting implications regarding both potential benefits and
risks. Our own previous advetse experience with intrave-
nous verapamil and beta-adrenergic blocking drugs (48) and
our demonstration that at clinical doses nifedipine lacks the
potent electrophysiologic effects seen with varapamil (49)
made us reluctant to combine verapamil with beta-receptor
blocking drugs. We therefore compared the effects of ni-
fedipine with those of propranolol, as well as the combi-
nation of both. In our study (43), we used nifedipine and
propranolol at two dose levels, respectively 30 and 60 mg/
day, and propranolol at levels of 240 and 480 mg/day; the
smaller and larger doses of each were combined with the
corresponding amounts of the other substance in crossover
studies. At each dose level propranolol proved slightly more
effective than nifedipine as judged from the incidence of
anginal attacks, the number of tablets of nitroglycerin con-
sumed and objective measurements of exercise-induced ST
segment depression and episodes of ST segment depression
during 48-hour periods of ambulatory electrocardiographic
monitoring. Most strikingly, however, the larger dose of
the combination of drugs was significantly more effective
than all other medications, and the improvement over pla-
cebo was striking (p < 0.0005 for all variables, with a re-
duction in the area of exercise-induced ischemia as judged
by precordial mapping and the frequency of ischemic events
detected by ambulatory monitoring by 90 and 95% re-
spectively, when comparing the high dose combination with
placebo). In another study (50), the total work that could
be performed increased by 41% when nifedipine at 30 mg/
day was combined with metoprolol or alprenolol. Two trials
(51,52) with verapamil and propranolol, assessing fewer
variables and in one case using a single rather than a double-
blind crossover study, suggest that, thetapeutically, vera-
pamil and propranolol together are also better than either
drug alone. The question of adverse effects, which proved
an important issue in one of these reports (52), will be
discussed in a later section.
Thus, although calcium antagonists do not appear to have
the same prime role in chronic stable angina as the evidence
suggests they have in variant and unstable angina, they can
be of subjective and objective benefit. Controlled trials are
too few to permit dogmatic statements, but the question of
an advantage for a beta-receptor blocking agent or calcium
antagonist is problematic at best, and our own limited but
intensive trial suggests that in many cases there will be
advantages if a single agent, a beta-receptor blocking drug,
is used (43). There are, however, attractive theoretical rea-
sons for preferring a combination of drugs (23), and evi-
dence favoring use of such a combination is growing. It
would be useful to see whether in future trials of such a
combination, each drug has a dose-sparing effect on the
other so that smaller amounts of each can be used, thus
possibly obviating some adverse effects.
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Mechanism ofAntianginal Action
Clearly. the mechanisms of benefit will vary according to
whether or not organic coronary artery disease is to a greater
or lesser extent primarily responsible for the decrease in
blood flow during angina. In exercise duration studies with
calcium antagonists. the rate-pressure product (heart rate
times systolic blood pressure) is similar to that in studies
with placebo; and even for a given work load no significant
difference is seen. which is unlike the situation that occurs
with beta-receptor blocking drugs (21,43,50). The increased
flow to areas of pacing-induced ischemia (23) may help.
explain the almost universal benefit seen when calcium an-
tagonists are given to patients with variant angina. This
increased flow may also explain the situation in patients
with chronic stable angina, in whom beta-receptor blocking
drugs may have the same effect or even advantages.
Protection Against Acute Ischemic Damage
Acute ischemic damage may lead to permanent change, be
this myocardial infarction in the context of impaired coro-
nary flow, or inadequate perfusion associated with cardio-
pulmonary bypass. At least in part because ischemia impairs
the mechanism whereby calcium is pumped out of the cell,
it leads to a high cytosolic calcium concentration (53,54).
This calcium overload leads to increased use of adenosine
triphosphate and impairment of mitochondrial function, so
that further production of this substance is decreased (53).
It is therefore reasonable to see whether prevention of
excess entry of calcium will protect the myocardium against
ischemia; indeed, beta-receptor blocking drugs seem to owe
some of their protective effect to inhibition of catechol-
amine-stimulated calcium influx (55). In experimental sit-
uations. this beneficial effect. in terms of demonstrable mit-
igation of ischemic damage. has been shown for several
calcium antagonists. notably verapamil and nifedipine (56-
58). A tendency toward reversal of the functional impair-
ment produced by ischemia, as judged by tension, contrac-
tility and systolic function at rest. has also been shown with
verapamil, nifedipine and diltiazem (59-61). Ischemia
produces increased cellular fragility in rabbit hearts, and
this is prevented by pretreatment with nifedipine (62). There
is a good experimental basis, therefore, for the use of cal-
cium antagonists for cardiopulmonary bypass. in preference
to potassium chloride (63), in order to prevent reperfusion
injury .
Arrhythmias
Supraventricular Arrhythmias
Supraventricular tachycardia. Just over a decade ago.
we reported the results of our first systematic investigation
that showed the considerable value of verapamil in the con-
version of paroxysmal reentrant atrioventricular tachycardia
(48) in slowing and regularizing atrial fibrillation and in
sometimes correcting atrial flutter (64). The prompt action
of verapamil in virtually all patients with paroxysmal su-
praventricular tachycardia is sometimes inhibited or antag-
onized by changes in autonomic tone occurring soon after
initiation of the tachycardia (65). Formal comparison with
crossover studies in patients with this arrhythmia showed
success in 19 of 20 patients with verapamil, as opposed to
only 8 of 20 given practolol (66). Successful termination
of the arrhythmia by intravenous verapamil does not nec-
essarily predict that oral prophylaxis with this agent will be
effective, but failure to terminate the arrhythmia with in-
travenous verapamil confidently indicates that oral prophy-
laxis will likewise fail (67,68). As previously indicated (49),
nifedipine lacks the electrophysiologic properties of vera-
pamil of prolonging atrioventricular nodal conduction and
ability to terminate reciprocating atrioventricular tachycar-
dia. Our preliminary studies (69) show that the electrophys-
iologic properties of diltiazem and verapamil tend to re-
semble each other; diltiazem should therefore be considered
to fall more into the category of verapamil and not to re-
semble nifedipine.
Atrial fibrillation and flutter. Intravenous verapamil
usually produces a transient increase in the degree of atrio-
ventricular block. conversion to sinus rhythm being rare
with fibrillation and uncommon with flutter (48). Some stud-
ies (70) have shown that oral verapamil can be used to
control the ventricular response satisfactorily in atrial fi-
brillation. Where digoxin or verapamil proves inadequate
in controlling the ventricular rate during atrial fibrillation,
these agents can be usefully given together (71). Because
verapamil causes an increase in the serum digoxin concen-
tration. explicable in part by a reduction in renal excretion
of digoxin without reduction in glomerular filtration (72),
care should be taken to adjust the dose of digoxin in patients
who are simultaneously given verapamil.
Ventricular Arrhythmias
Electrophysiologic studies (73) have led to the theoretical
suggestion that some ventricular arrhythmias arise because.
under the influence of ischemia. myocardial cells depolarize
by way of the slow as opposed to the fast inward channel,
a reaction that is blocked by verapamil. Other and more
recent studies (74) have contradicted this view, at least as
far as the His-Purkinje system is concerned; and indeed, in
other studies using models of myocardial infarction. vera-
pamil has not proved effective (75). Of clinical relevance
is the failure of verapamil to inhibit chronic recurrent ven-
tricular tachycardia during electrophysiologic testing (76).
Though some ventricular extrasystoles are suppressed by
intravenous verapamil (64). this agent has not been shown
to be of clinical value against more serious ventricular ar-
rhythmias (71).
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When ventricular arrhythmias arise after coronary spasm.
relief of the spasm by calcium antagonists has secondary
antiarrhythmic value (78); the decrease in reperfusion-in-
duced ventricular arrhythmias seen experimentally with ver-
apamil may be relevant to this finding (79). Once again.
there appears to be a difference between verapamil and
nifedipine in relation to antiarrhythmic properties (49.79).
though the latter report requires corroboration in the clin-
ical context. Indeed. experimental evidence that verapamil
protects against the ventricular fibrillation produced in dogs
by coronary artery occlusion or by release of this occlusion
(80.81) still requires clinical validation that is difficult to
achieve.
Role of verapamil. The antiarrhythmic effects of ver-
apamil are important; in fact, this agent has been categorized
as the prototype of a fourth kind of activity in the classi-
fication propounded by Vaughan Williams (82). Apart from
other members of the same chemical family. diltiazem ap-
pears to be the calcium antagonist that also tends to have
this effect. which is not common to all calcium antagonists
as evidenced by the lack of such antiarrhythmic properties
of nifedipine (49). There is a definite role for verapamil in
supraventricular arrhythmias, for which it appears to be the
best currently available agent in the treatment of paroxysmal
supraventricular tachycardia; calcium antagonists have not
proved of direct value for ventricular arrhythmias despite
some theoretical suggestions that have been made.
Hypertension
It has recently been suggested that a sodium transport in-
hibitor might be important in hypertension and be linked
with excessive entry of calcium into the vascular smooth
muscle (83); in keeping with this observation is the fact that
the calcium antagonists nifedipine and verapamil cause a
greater reduction in blood pressure in hypertensive subjects
than in normal subjects (84,85). In hypertensive patients.
30 mg of nifedipine produced a decrease of approximately
28% in both systolic and diastolic blood pressure, accom-
panied by an increase in heart rate of 17% and an increase
in plasma renin activity; both effects were blocked by pro-
pranolol. which also caused a further slight reduction in
blood pressure (86). In our own double-blind studies (85),
nifedipine taken for a month (30 mg/day for 2 weeks, fol-
lowed by 60 mg/day for 2 weeks) reduced supine and stand-
ing systolic and diastolic blood pressure by 15 and 20% and
by 21 and 23% respectively; in these and other long-term
studies there was no increase in heart rate. Important dose-
dependent reductions in blood pressure also have been seen
with verapamil, both in double-blind placebo-controlled
crossover studies and in studies in which this agent was
substituted for existing drugs; again these long-term studies
were not associated with significant increases in heart rate
(87-89). We and others (85,90.91) have found additional
benefit, with attenuation of some of the adverse effects seen
with nifedipine, when this agent has been combined with
beta-receptor blocking drugs for the treatment of hypertension.
Though the use of calcium antagonists to manage hy-
pertension has attracted less attention than has their use in
the management of ischemic heart disease and arrhythmias,
there is a growing body of evidence providing both theo-
retical and practical indication of their value. either alone
or in combination with beta-receptor blocking drugs. Other
interactions clearly need study in view of the large number
of medications already in use for hypertension. The evidence
suggests good tolerance and efficacy. and specific additional
benefits in those hypertensive patients suffering from symp-
tomatic ischemic heart disease.
Hypertrophic Cardiomyopathy
Effect on left ventricular hypertrophy. In the light.
perhaps, of theoretical considerations related to increased
transmembrane calcium flux in the hereditary cardiomy-
opathy of Syrian hamsters (92). Kaltenbach et al. (93) gave
long-term oral verapamil to patients with hypertrophic
cardiomyopathy whose left ventricular hypertrophy had re-
mained unchanged or become worse while receiving pro-
pranolol; after the switch to verapamil substantial regression
of hypertrophy was seen, as judged mainly by plain ra-
diography and electrocardiographic criteria. The same workers
(94) have shown similar results in longer studies on 22
patients given a mean oral daily dose of verapamil of 480
mg for an average of 15 months. In this study. some patients
underwent echocardiographic assessment, and in 10 patients
cardiac catheterization was repeated; the left ventricular muscle
mass was decreased in 7 of these 10. From 39 patients fol-
lowed up over a mean period of 26.4 months, favorable
results were confirmed.
Effect on ventricular function. Exercise capacity was
improved in patients with hypertrophic cardiomyopathy given
verapamil, and this increased capacity was related to an
improvement in the abnormal left ventricular diastolic filling
seen in this condition, there being no alteration in systolic
function (95). While the investigators (96) noted substantial
subjective improvement during long-term treatment with
verapamil, they did not see improvement in echocardio-
graphic measurements in 31 patients treated for 1 year. an
experience different from that of the German workers (94).
Although there was improved systolic performance and di-
astolic function, as judged echocardiographically in 15 pa-
tients given sublingual nifedipine (97), the combined admin-
istration of nifedipine and propranolol appeared to be superior
as judged at hemodynamic study in 12 patients (98).
Effect on arrhythmias. Although there are several re-
ports of subjective and objective improvement. the latter in
terms of cardiac function, when calcium antagonists are
administered to patients with hypertrophic cardiomyopathy,
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such treatment may provide only limited protection again st
the most lethal consequences of the disorder. In 19 patient s
with hypertrophic cardiomyopathy complicated by refrac-
tory arrhythmias, verapamil failed to reduce the incidence
of arrhythmia, whether supraventricular or ventricular, in
contradistinction to another antiarrhythmic agent, amioda-
rone (99). An important area in which theoretical consid-
erations had suggested additional value thus has not been
confirmed in practice.
Heart Failure
Even though the direct intracoronary admini stration of ni-
fedipine produces a negative inotropic effect, such change s
are overcome on intravenous injection by virtue of the reflex
increases in contractility and heart rate that occur as a result
of lowering systemic arterial pressure (100). After sublin-
gual adm inistration of nifedipine to patients with ischemic
heart disease with depressed left ventricular function , no
discernible adverse effects were noted (101 ). In 14 patients
with left ventricular dysfunction subjected to an exerci se
test before and 60 minutes after taking 30 mg of nifedipine
sublingually, pulmonary artery pressures, which did not
change at rest , decreased sign ificantly during exercise, prob-
ably owing to a shift in left ventricular pressure-volume
relations (102). Despite these promising observations and
occasional success in the clinical management of heart fail-
ure (103 ), great prudence is neces sary while the role of such
agents receives much more careful and exten sive evaluation .
Primary Pulmonary Hypertension
The treatment of primary pulmonary hyperten sion with va-
sodilators has produced mixed results. Some workers (104 )
reported benefit with oral nifedipine on the basis of an initial
favorable acute hemodynamic response. Others (lOS, 106),
and indeed these original authors, have now reported that
such effects are inconsistent , that a positive hemodynami c
response does not always predict clinical benefit and that
right ventricular failure might be induced . It is concei vable
that greater systemic vasodilatation of healthy vessels may
contribute toward such adverse effects , though individual
cases may show benefit.
Side Effects
Sinoatrial depression. Understandable concern has aris-
en since the occasional observation of sinoatrial depression
in patients given verapamil intravenously for the termination
of paro xysmal supraventricular tachycardia, but the expla-
nation is usually clear: either the patient has concomitantly
received beta-adrenergic blocking agents or has sinoatri al
disease (48) . Verapamil therefore should not be given under
these circumstances (107), and it is prudent that on the first
occasion it is given to a patient with paroxysmal supra-
ventricular tachycardi a, appropriate treatment be available
in case sinoatrial disease is present. We have seen no evi-
dence of sinoatrial depre ssion with nifedipine wheth er given
alone or in combination with propranolol (85). Should hy-
potension occur after intravenous verapamil is given for
paroxysmal supraventricular tachycardia . it is usually mild
and transient (64) .
Negative inotropic effects. Although concern has been
expre ssed about the negative inotropic effects of calc ium
antagonists. these effects have not caused major difficulty;
indeed, verapamil has been given without ill effect to pa-
tient s with myocardial infarction ( 108). As already indi-
cated , any negative inotropic effect is usually counterbal-
anced by reflex sympathetic drive (\ 00-1 02). Fears have
been expre ssed that the simultaneous administration of a
beta-receptor blocking agent might have ill effects, perhaps
by interfering with such respon ses: though there are isolated
case reports from which one might suspect the combination
of nifedipine and beta-receptor blocking agent s to cause
hypotension or heart failure (l09-11 2), this has not . in
practice , proved an important probl em (85) . Many of these
report s are anecdotal and lack full hemodynamic informa-
tion and should be balanced again st careful observations
made to test the situati on. In one such study (\ 13), 12
patients underwent cardiac catheterization for the investi-
gation of chest pain; though 8 were found to have coronar y
artery disease , none was shown to have any impairment of
left ventricular function . The heart rate was then kept con-
stant by right atrial pacing at 100/min . While nifedipine
depressed the peak first derivative of left ventricular pressure
(dP/dt), it also significantly decreased systemic vascular
resistance . Nifedipine therefore increased cardiac output in
association with arterial dilatation despite evidence for a
negative inotropic effect ; once again. the intrinsic negative
inotropic effects under these circumstances need assessment
in patients with impaired myocardial output , an aspect we
are explor ing at present. Th is is strongly supported by a
careful study (114 ) in which combined treatment with ace-
butolol and nifedipine in patient s with chronic coron ary
artery disease was assessed: in 21 patients with angio graph-
ically documented coronary artery disease and stable angina.
simultaneous hemodynamic and radionucl ide ventriculo-
graphic measurements were made at rest and during exercise
before treatment, as well as 30 minute s after the admini s-
tration of nifedipine or acebutolol. or the combination. The
negative inotropic effects of the beta- adrenergic blocking
drug were balanced by the nifedip ine and no adverse ef fects
were seen in patients with borderline heart failure .
While Leon et al. (5 1) noted no adverse effect s from the
combination of oral verapamil and propranolol in II patients
with angina, there may be some concern when myocardial
function is depressed (\ 15). and it is worrying that 7 of 40
patients similarly treated developed hypotension or heart
failure and that sinus node depression was observed appar-
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ently in the short term in 4 additional patients (52). Sig-
nificant negati ve inotropic and chronotropic effects , but no
untoward symptoms, were also seen in 15 patient s durin g
a 3 day trial of this combination (116). Clearly, howe ver ,
more careful and prolonged studie s under clinical conditions
will be required to assess the benefit s and potential disad-
vantages of such combinations.
Specific adverse effects that also requ ire consideration
are the occasional anecdotal report s of chest pain followin g
nifedipine , which are difficult to assess (117). and problems
with verapamil in hypertrophic cardiomyopath y. Epstein
and Rosing (118 ) encountered serious hemodynamic com-
plications in patients with this disorder and caution again st
use of verapamil in patients who have a high pulmonary
capillary wedge pressure, paroxysmal nocturnal dyspnea or
orthopnea in the presence of left ventricular outflow ob-
struct ion. or sinoatrial or atrioventricular disease unless a
pacemaker has been implanted.
Noncardiac untoward effects. These are few; in the
case of verapam il, constipation may be a nuisance , and with
nifed ipine , ankle edema apparently result ing from peripheral
vasodilatation (85) . Interestingl y. in this study we noted that
ankle edema was seen in fewer patient s taking the combi-
nation of nifedipine and propranolol . and also that those
who developed coldness of the limbs with propranolol treat-
ment were less troubled by it while taking the combination
of drug s.
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